2 results
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
Approved WMOCompleted
To evaluate the efficacy, safety, pharmacology, and patient-reported outcomes of the combination of taselisib plus fulvestrant compared to placebo plus fulvestrant in ER+, HER2- postmenopausal women with locally advanced or MBC and who have had…